A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)

Next Previous
Trial Profile

A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Tefinostat (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MONOCLE

    • Most Recent Events

    • 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top